IVERIC bio, Inc. (ISEE)
| Market Cap | 1.55B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -141.38M |
| Shares Out | 116.42M |
| EPS (ttm) | -1.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 332,847 |
| Open | 13.55 |
| Previous Close | 13.60 |
| Day's Range | 13.15 - 13.55 |
| 52-Week Range | 8.37 - 19.35 |
| Beta | 1.52 |
| Analysts | Buy |
| Price Target | 24.94 (+87.2%) |
| Earnings Date | Jul 26, 2022 |
About ISEE
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for ISEE stock is "Buy." The 12-month stock price forecast is 24.94, which is an increase of 87.24% from the latest price.
News
Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Pravin U. Dugel, M.D., President, will participate in a panel discussion at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference.
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced the Company will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022.
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.
Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the second quarter ended June 30, 2022 and provided a general business update.
Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silico...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that it has entered into a term loan debt financing facility with Hercules Capital, Inc. and Silicon Valley Bank.
Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022.
Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialis...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric presented results from a post-hoc analysis from the GATHER1 clinical trial of Zimura at American Society of Retina Specialists Meeting.
Trial Results Set to Make or Break Small-Cap Pharma Stocks
One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration...
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®
PARSIPPANY, N.J. & TURKU, Finland--(BUSINESS WIRE)--Iveric entered into a global license agreement with DelSiTech to develop new formulations of Zimura using DelSiTech's sustained release technology.
Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Pa...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced its presentation of a post-hoc analysis from the Zimura GATHER1 clinical trial at the Macula Society Meeting in Berlin, Germany.
Iveric Bio to Present at the UBS Global Healthcare Conference 2022
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that Pravin U. Dugel, M.D., will participate in a fireside chat at the UBS Global Healthcare Conference 2022 on May 23, 2022.
Iveric Bio to Participate in the H.C. Wainwright Global Investment Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that Pravin U. Dugel, M.D., President, will present a corporate overview at the H.C. Wainwright Global Investment Conference.
Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the first quarter ended Mar. 31, 2022 and provided a general business update.
Iveric Bio Announces Presentation of Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geogra...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that a post-hoc analysis from its GATHER1 clinical trial of Zimura will be presented at Renal World Congress on May 13, 2022.
Iveric Bio to Report First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 4, 2022
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022.
Iveric Bio to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio will participate in a fireside chat at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022.
Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks
Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the bac...
Iveric Bio to Present at the Cowen 42nd Annual Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that Glenn P. Sblendorio, CEO, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 7.
Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2021 and provided a general business update.
Iveric Bio to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, Februa...
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022.
Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geograp...
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced a post-hoc analysis from the GATHER1 Zimura Phase 3 clinical trial, which evaluated various GA growth parameters.
Iveric Bio Announces New Post-Hoc Analyses of Zimura® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Ex...
NEW YORK--(BUSINESS WIRE)--Iveric announced that new post-hoc analyses from the GATHER1 Zimura® Phase 3 trial will be presented at Angiogenesis, Exudation, and Degeneration 2022
Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio
MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today that Preside...
Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced today the election of Christine Ann Miller to its Board of Directors, effective immediately.